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BACKGROUND: D-Glucuronyl C5-epimerase (GLCE) is a key enzyme involved in the biosynthesis of heparan sulphate proteoglycans,
which has an important role in cell–cell and cell–matrix interactions and signalling. Decreased GLCE expression in human breast
tumours and its anti-proliferative effects in breast cancer cells suggest that it may be a candidate tumour-suppressor gene. The aim of
this study was to investigate the involvement of GLCE in lung carcinogenesis.
METHODS: D-Glucuronyl C5-epimerase expression in different lung cancer cell lines was determined and the gene was ectopically
re-expressed in U2020 small-cell lung cancer cells. Cellular proliferation in vitro and tumour growth in vivo were then examined.
RESULTS: Ectopic re-expression of GLCE in U2020 cells did not affect cell viability but did influence morphology. Cellular proliferation
in vitro and tumour formation in vivo were both suppressed. These effects were mediated via downregulation of several
pro-angiogenic growth factors and their receptors, including VEGF-A, TGFB1, FGFR2, PDGF-A and PDGF-B, and TNFa and its
receptors. Expression of matrix metalloproteinase2, MTA1, PLAU, TIMP3, S100A4, SERPINE1 and TWIST1 was also downregulated.
CONCLUSION: The anti-tumour effects associated with ectopic GLCE re-expression suggest that it may be a potential
tumour-suppressor gene and a possible target for lung cancer diagnosis and treatment.
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Lung cancer is one of the most common cancers worldwide in
terms of both incidence and mortality, with 1.35 million new cases
and 1.18 million deaths per year. Numerous attempts have been
made to find reliable molecular markers and possible new targets
to treat the disease (Hann and Rudin, 2007); however, despite
extensive studies, the molecular mechanisms underlying lung
carcinogenesis remain unclear (Rosti et al, 2006; Pastorino, 2010).
The aim of the present study was to examine the possible
involvement of D-glucuronyl C5-epimerase (GLCE) in the develop-
ment of lung cancer. D-Glucuronyl C5-epimerase is one of the key
enzymes involved in the biosynthesis of heparan sulphate (HS): the
polysaccharide moiety of complex HS proteoglycan (HSPG)
molecules. Heparan sulphate proteoglycans are widely expressed
on cell surfaces and within the extracellular matrix (ECM). They
have important roles in cell–cell and cell–matrix interactions
and signalling through their interactions with various proteins,
including growth factors and their receptors (Ori et al, 2008). The
most common HSPGs are syndecans (Alexopoulou et al, 2007),
glypicans (Filmus et al, 2008), perlecan (Whitelock et al, 2008),
collagen XVIII and agrin (Iozzo, 2005). Abnormal expression or
dysregulated function of HSPGs is involved in cancer and
angiogenesis, and is crucial for the evolution of the tumour
microenvironment (Iozzo et al, 2009).
At present, the functional contribution of glycosylation
(particularly proteoglycans) to lung carcinogenesis is unclear;
although the pattern of HSPG expression is significantly altered in
lung tumours and may contribute to their invasive phenotype
(Nackaerts et al, 1997), and the expression of the candidate
tumour-suppressor gene, glypican-3, is absent in all the non-small-
cell lung carcinoma cell lines tested to date (Kim et al, 2003).
However, because there are few reliable and sensitive methods
available for investigating the role of glycosylation, the majority of
studies have only looked at the HSPG protein core. Nevertheless, in
many cases, glycosylation is a major determinant of HSPG
function (Blackhall et al, 2001; Reijmers et al, 2010). An alternative
approach to the problem could be to study the biosynthetic
machinery for HS, as defects in biosynthesis would, presumably,
affect all HSPGs (Lander and Selleck, 2000).
Little is known about the functional role of HS biosynthetic
enzymes in carcinogenesis, and GLCE is the least studied of all
the enzymes (Nadanaka and Kitagawa, 2008). D-Glucuronyl
C5-epimerase is responsible for the epimerisation of D-glucuronic
acid (D-GlcUA) to form L-iduronic acid (L-IdoUA), which provides
flexibility to the HS chains and is important for their interactions
with various growth factors (Catlow et al, 2008; Jia et al, 2009).
D-Glucuronyl C5-epimerase has been cloned from bovine lung
cDNA (Li et al, 1997), murine liver (Li et al, 2001) and mouse
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smastocytoma cell line cDNA libraries (Crawford et al, 2001).
Murine (NM_033320), bovine (NM_174070) and human
(NM_015554) epimerase cDNAs are 82–86% homologous at the
nucleotide level and 96–99% homologous at the amino-acid
level. Chromosome mapping suggests the occurrence of a single
epimerase gene on chromosome 15q23 (Li et al, 2001). The
involvement of GLCE in the aetiology and pathology of human
disease is not known.
Recent studies show decreased expression of GLCE in human
breast tumours (Eshchenko et al, 2007; Grigorieva et al, 2008).
Ectopic expression of GLCE inhibits the proliferation of MCF7 cells
in vitro through attenuated expression of the different genes
involved in cell cycle regulation, angiogenesis and metastasis
(Prudnikova et al, 2010). These data support the involvement
of the gene in breast carcinogenesis.
According to the data presented at http://www.genecards.org/
cgi-bin/carddisp.pl?gene¼GLCE&search¼GLCE, another tissue
showing relatively high GLCE expression is human lung. Targeted
disruption of the GLCE gene in mice results in structurally altered
HS, which lacks IdoA and carries a lethal phenotype resulting in
lung defects, renal agenesis and skeletal malformations (Li et al,
2003). These data suggest that appropriate GLCE expression/
activity is particularly important in lung tissues; thus, we
hypothesised that dysregulation of GLCE expression in human
lung tissue may be a significant factor in the aetiology and/or
development of malignancy.
In this study, we investigated the expression levels of GLCE in
different lung cancer cell lines and ectopically expressed GLCE in
the small-cell lung cancer cell line, U2020. The proliferation rates
of the cells in vitro and tumour growth in vivo were studied, as well
as the possible molecular mechanisms of the functional effect
of GLCE in lung cancer.
MATERIALS AND METHODS
Cell lines and cell culture
The U2020, A549, H157 and H647 human lung cancer cell lines
were obtained from MTC (Karolinska Institute, Stockholm,
Sweden). The A716 cell line was a kind gift from Professor M
Lerman (Center for Cancer Research, National Cancer Institute,
Frederick, MD, USA). All cell lines were maintained in Iscove’s
Modified Dulbecco’s medium (IMDM) supplemented with
L-glutamine, 100unitsml
 1 penicillin, 100mgml
 1 streptomycin
and 10% FBS at 371C in a humidified 5% CO2 incubator. Cells were
harvested for passaging or analysis using trypsin/EDTA.
Analyses of GLCE expression using RT–PCR
Total RNA was extracted from the cells using the PureLink Total
RNA Purification System (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. cDNA was synthesised from
1–2mg of total RNA using a First Strand cDNA Synthesis kit
(Fermentas, Hanover, MD, USA) and 1/10th of the product was
subjected to PCR analysis.
The following conditions were used for multiplex RT–PCR:
951C for 10min, 951C for 15s, 591C for 15s and 721C for 1min,
with a final elongation step at 721C for 10min using a Tercik PCR
machine (DNA-technology, Moscow, Russia). The total reaction
volume was 20ml. D-Glucuronyl C5-epimerase and GAPDH (house-
keeping gene) were amplified for 32 and 20 cycles, respectively.
The amplified products were separated on 1.2% agarose gels. The
gels were scanned using the ‘DNA Analyzer’ system (Vilber
Lourmat, Marne-la-Valle, France) and epimerase expression levels
were estimated from the intensity of the amplified GLCE DNA
fragment normalised against the intensity of GAPDH (TotalLab
programme, Nonlinear Dynamics, Newcastle upon Tyne, UK). The
PCR primers used for human GLCE and GAPDH were as follows:
GLCE-F, 50-AAGGGAGACGAGAGGGGAACGAA-30; GLCE-R, 50-G
CCACCTTTCTCATCCTGGTTC-30; GAPDH-F, 50-GGGCGCCTGGT
CACAA-30; GAPDH-R, 50-AACATGGGGGCATCAGCAGA-30.
Quantitative real-time RT–PCR (qRT–PCR) was performed using
the BioRad IQ5 Multicolor Real-Time PCR Detection System
(BioRad, Hercules, CA, USA) and the GLCE TaqMan Custom Assay
(Applied Biosystems, Foster City, CA, USA) under the following
conditions: 951C for 3min, followed by 40 cycles at 951C for 10s
and 601C for 30s. The total reaction volume was 25ml. b-actin
(ACTB) was used as the housekeeping gene. The PCR primers and
TaqMan probes used were: GLCE-F, 50-TTCCAAAGTCTATGCAC
AGAGAGC-30; GLCE-R, 50-TCCACATTGTAGCCTTCAAAAGACA-
30; GLCE probe, 50-FAM-CCCCTATCACCCCGATGGT-TAMRA-30;
b-actin-F, 50-GGCACCCAGCACAATGAAG-30; b-actin-R, 50-GCCG
ATCCACACGGAGTACT-30; b-actin-probe, 50-FAM-TCAAGATC
ATTGCTCCTCCTGAGCGC-TAMRA-30.
Construction of the epimerase-expression plasmid
Human GLCE (NM_015554) was cloned into the episomal vector,
pETE/Bsd (Protopopov et al, 2002). The full-length GLCE cDNA
sequence was amplified from the KIAA0836 clone (AB_020643)
encoding the 50-truncated sequence of GLCE (Kazusa DNA
Research Institute, Chiba, Japan) by PCR using Pfu-DNA-
polymerase (Stratagene, La Jolla, CA, USA) and the epi-oligo-
F5 0-CTAAGATCTAGATATGCGTTGCTTGGCAGCTCGGGTCAACT
ATAAGACTTTGATTATTA-30 and epi-R 50-TACAGCGGCCGCT
GAAGTGCAGTTTTGGT-30 primers. The amplified full-length DNA
fragment was then cloned into the pETE/Bsd vector at the BglII and
NotI sites. The GLCE sequence was verified by sequencing (Dye
Terminator Cycle sequencing Kit and an ABI PRISM 3700 Genetic
Analyzer, Applied Biosystems, Foster City, CA, USA).
Transfection and selection of stably transfected
epi-U2020 cell clones
To obtain stable cell clones expressing GLCE, U2020 cells
were transfected with epi-pETE/Bsd or pETE/Bsd plasmid DNA
(0.5mg DNA per well) in 12-well plates using Lipofectamine and
Plus Reagent (Invitrogen) according to the manufacturer’s
protocol. Transiently transfected epi-U2020 and pETE-U2020 cells
were cultured for 2–3 weeks in IMDM medium containing Bsd
(5mgml
 1) to select stable clones.
Immunocytochemistry
For immunofluorescence, cells were grown on glass coverslips and
then fixed with 4% formaldehyde. The anti-GLCE custom
rabbit polyclonal serum (GenScript Corporation, Piscataway, NJ,
USA) was used for immunostaining. Staining patterns were
visualised with TexasRed-conjugated antibody against rabbit IgGs
(Vector Laboratories, Burlingame, CA, USA) (1:1000 dilution).
The nuclei were mounted and counterstained with DAPI using
SlowFade Gold with DAPI mounting medium (Invitrogen) and
observed by fluorescent microscopy (Axio Imager, Carl Zeiss UK,
Hertfordshire, UK).
Colony formation assay
Transiently transfected cells were stripped 24–48h after transfec-
tion and plated on 100mm
2 cell culture dishes at a density of
500–1000 cells per plate. After selection with Bsd (5mgml
 1),
Giemsa-stained colonies were photographed and counted using
Quantity One software (version 4.4.0; Bio-Rad, Hercules, CA, USA).
Growth curve assay
The growth curves for the U2020 cells transiently transfected with
epi-pETE/Bsd or pETE/Bsd plasmid DNA were monitored by
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sdirect cell counting. The cells were seeded at 10
4 cells per well in
6-well plates 24h after transfection, detached using 0.25% trypsin
every 24h and counted using a Coulter Counter (Beckman Coulter,
Brea, CA, USA).
In vitro cell proliferation assay
Cell proliferation rate was determined using the CyQUANT NF Cell
Proliferation Assay (Invitrogen) according to the manufacturer’s
protocol. Briefly, cells were plated in a 96-well microplate at
densities of 100–500 per well (8–12 identical wells in total) and the
DNA content of the wells was measured every 24h. This was
achieved by removing the medium and adding 50ml of fluorescent
dye followed by incubation for 30min at 371C. The fluorescence
intensity of each sample was measured at 485/530nm using
fluorescence microplate reader (SPECTRA max, Molecular
Devices, Sunnyvale, CA, USA).
Tumour growth in SCID mice
The tumourigenicity of epimerase-transfected U2020 and control
pETE-U2020 cells was assessed by subcutaneously injecting the
cells into 6–8-week-old SCID mice as previously described
(Protopopov et al, 2002). Cell inoculation, monitoring of tumour
growth and animal care were undertaken at the Karolinska
Institute Animal House according to the Institutional guidelines.
Briefly, cells were collected by centrifugation at 800r.p.m. for 2min
and resuspended in serum-free IMDM medium at a concentration
2–3 10
6 cells per 100ml injection. The cells were inoculated
together with a Matrigel matrix (BD Biosciences, Erembodegem,
Belgium) according to the manufacturer’s protocol. Mice were
observed for tumour formation twice per week and the tumour size
was measured using callipers.
Cancer PathFinder RT2 Profiler PCR array
The Cancer PathFinder RT2 Profiler PCR array (SABioscience,
Frederick, MD, USA) was used to identify the molecular
mechanisms underlying the anti-proliferative effects of GLCE.
Briefly, total RNA was isolated using a RNAqueous Micro Kit
(Applied Biosystems). The RNA concentration was determined
using a Quant-iT Assay Kit for RNA quantification (Invitrogen)
and was verified by electrophoresis. cDNA was synthesised from
1–2mg of total RNA using a First Strand cDNA Synthesis kit
(Fermentas). Real-Time PCR was performed using an RT2 Profiler
PCR Array System with SYBR Green PCR Master Mix (Fermentas)
and an iCycler iQ5 Multicolor Detection System (Bio-Rad)
according to the manufacturer’s instructions. All data were
analysed using Excel-based PCR Array Data Analysis Software
(SABioscience). This integrated web-based software package
automatically calculates ddCt-based fold changes in genes expres-
sion from the uploaded raw threshold cycle data. Each replicate
cycle threshold (Ct) was normalised to the average Ct of five
endogenous controls (B2M, HPRT1, RPL13A, GAPDH and ACTB)
on a per plate basis.
RESULTS
D-Glucuronyl C5-epimerase expression is decreased in lung
cancer cells
Multiplex and quantitative RT–PCR analysis was used to study
GLCE expression in lung cancer cells. Specific primers and
TaqMan probes for the exon 2–3 boundary region of the GLCE
gene (which appears to be affected in human tumours) were used
(Grigorieva et al, 2008). D-Glucuronyl C5-epimerase expression was
examined in U2020 (small-cell lung carcinoma), A716, A549,
H647 and H157 (non-small-cell lung cancer) cells. Normal human
lung cDNA (Clontech, San Diego, CA, USA) was used as a
control for epimerase expression in normal lung tissues
(Figures 1A and B).
According to the multiplex RT–PCR data, the GLCE expression
levels in all of the tested cell lines was three to four times lower
than in normal lung tissue (Figure 1A). The effect was quantified
using TaqMan-based qRT–PCR, and GLCE expression was
determined to be 1100–1200 epimerase molecules per 1000 actin
molecules in normal lung tissue and 100–200 epimerase molecules
per 1000 actin molecules in the lung cancer cell lines (Figure 1B).
These results clearly show that GLCE expression is significantly
decreased (five to six times) in lung cancer cell lines compared
with normal human lung tissues.
D-Glucuronyl C5-epimerase re-expression suppresses
U2020 cell proliferation but not viability in vitro
To study the functional role of GLCE in lung cancer, the gene was
ectopically expressed in U2020 cells. As a first step, full-length
GLCE cDNA was cloned into the episomal vector pETE/Bsd for the
effective ectopic expression of GLCE in mammalian cells. The
obtained DNA plasmid was designated as epi-pETE/Bsd. U2020
cells were transiently transfected with either epi-pETE/Bsd
(epi-U2020) or an empty pETE/Bsd control vector (pETE-U2020)
and subjected to colony formation assay and growth curve assay
(Figure 2).
Colony formation was evaluated in monolayer cultures. The
number of colonies formed by the epi-U2020 cells was similar to
that formed by the control pETE-U2020 cells (Figures 2A and B).
However, there was a significant difference in growth time between
the epi-U2020 and the pETE-U2020 clones (6 weeks and 2 weeks
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Figure 1 D-Glucuronyl C5-epimerase expression in human lung cancer cell
lines. (A). Multiplex RT–PCR. Intensity of the amplified epimerase DNA
fragments normalised to that of GAPDH. A representative gel is shown
(inset). (B) Quantitative real-time RT–PCR. D-Glucuronyl C5-epimerase
expression in normal human lung and lung cancer cell lines (U2020, A716,
A549, H647 and H157).
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sbetween transfection and plate staining, respectively). To investi-
gate the possible reasons for this difference, the proliferation of
U2020 cells transiently transfected with either the epi-pETE/Bsd or
the control pETE/Bsd plasmids was estimated using a growth curve
assay (Figure 2C). The results showed that transfection with the
epi-pETE/Bsd plasmid impaired U2020 cell proliferation compared
with the control pETE-U2020 cells.
To further study the anti-proliferative effects of GLCE in U2020
cells, stable epi-U2020 and pETE-U2020 clones were selected.
These clones were checked for GLCE expression using multiplex
RT–PCR and the clones with the highest epimerase expression
(clones 4, 7 and 8) were used for the subsequent experiments
(Figures 3A and B).
The restored epimerase mRNA levels in the stable epi-U2020
clones were significantly higher than those in the control pETE-
U2020 clones, and were very similar to those in normal human
lung tissue. The presence of GLCE protein in the epi-U2020 cells
was verified by immunocytochemical staining using a custom
anti-epimerase polyclonal antibody (Figure 3D). Interestingly, the
stable epi-U2020 clones were morphologically different from the
control pETE-U2020 clones (Figure 3C), whereas the control clones
showed the same morphology as the original U2020 cells.
The proliferation rate of the stable epi-pETE and pETE-U2020
clones was determined using the CyQUANT NF Cell Proliferation
Assay based on the cellular DNA content measured by binding
of the fluorescent CyQUANT GR dye (Figure 3E). The stable
epi-U2020 clones (4, 7 and 8) proliferated five to six times more
slowly than the control pETE-U2020 cells. These results showed
that the selected stable epi-U2020 clones expressed GLCE at levels
similar to that in normal human lung tissue, and that ectopic
re-expression of GLCE in U2020 cells did not change their viability,
but did affect their morphology and proliferation rate in vitro.
D-Glucuronyl C5-epimerase inhibits U2020 tumour
xenograft growth in vivo
Epimerase-expressing U2020 cells (clones 4, 7 and 8) were
inoculated into SCID mice to study the effects of GLCE on the
growth of experimental lung tumours in vivo. U2020 cells stably
transfected with an empty vector (pETE-U2020) were used as a
control. Almost all the xenograft tumours grew more slowly than
the control tumours (Figure 4A), or failed to grow at all. Over the
course of 31–35 days, solid tumours were detected in 5 of 6 mice
inoculated with pETE-U2020 cells (control tumours), but in only 5
of 10 mice inoculated with epi-U2020 cells. All the tumours
(including the controls) were explanted and epimerase expression
determined using multiplex RT–PCR and qRT–PCR (Figures 4B
and C). The grown epi-U2020 xenograft tumours showed almost
no epimerase expression, although the epi-U2020 cells used
for the initial injections did show ectopic epimerase expression
at levels similar to those in normal lung tissue (Figures 4B and C).
qRT–PCR confirmed the multiplex RT–PCR data, estimating
GLCE expression in the initial epi-U2020 cells to be 720–960
epimerase molecules per 1000 GAPDH molecules, and almost no
epimerase expression in the grown epi-U2020 xenograft tumours.
Interestingly, slow-growing xenografts showed higher epimerase
expression (similar to that of the initial epi-U2020 cells; Figures 4B
and C), indicating that epimerase inactivation in the growing
experimental tumours may have been necessary for cancer
progression.
These results show that GLCE expression in U2020 cells inhibits
the growth of U2020 xenograft tumours in SCID mice and suggests
that GLCE may be a potential, novel tumour-suppressor gene.
D-Glucuronyl C5-epimerase affects lung cancer cell
proliferation and tumour growth by inhibiting tumour
angiogenesis and invasion/metastasis pathways
To further elucidate the molecular mechanisms underlying the
anti-proliferative effects of GLCE in small-cell lung cancer, we used
the Cancer PathFinder RT Profiler PCR Array. This new high-
throughput tool allows researchers to simultaneously profile the
expression of a panel of 84 cancer-related genes involved in
6 different molecular pathways and combines the quantitative
performance of SYBR Green-based RT–PCR with the multiple
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Figure 2 Effects of GLCE on the viability and proliferation of U2020 cells
in vitro.( A) The colony formation efficiency of epi-pETE- and pETE-
transfected U2020 cells (transient transfection). Original plates stained with
Giemsa are shown. (B) Quantitative analysis of colony numbers for the
epi-U2020 and control pETE-U2020 plates. The number of colonies on
the control pETE-U2020 plates was set as 100%. The histogram shows the
average colony numbers from triplicate experiments. Statistical analysis
was performed using OriginPro 8.1 (data represent the mean±s.d.).
(C) Representative multiplex RT–PCR experiment showing the expres-
sion of GLCE.( D) Proliferation of epi-U2020 and pETE-U2020 cells
(Growth curve assay).
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sgene-profiling capabilities of a microarray. The relative expression
levels of each gene in the two samples are plotted against each
other in a Scatter Plot (sample 1/control sample) and pair-wise
comparison yields a fold change in the expression of the genes
being studied.
We performed this analysis to look for genes whose expression
was changed in epimerase-expressing U2020 cells compared with
control pETE-U2020 cells. The results showed that the expression
of 32 genes was either down- or upregulated by more than
two-fold, while the expression of the remaining 52 genes was
unaffected (Figure 5).
According to the Cancer PathFinder RT Profiler PCR Array,
most of the affected genes are involved in apoptosis, angiogenesis
and invasion/metastasis pathways.
Of the genes involved in apoptosis, TERT was downregulated
4.5-fold, APAF1 2.4-fold, HTATIP2 3.5-fold, and TNFa and the
TNF receptors (TNFRSF10B, TNFRSF1A and TNFRSF25) 3–4-fold.
Of those involved in angiogenesis, VEGF-A was downregulated
6.2-fold, TGFB1 3.1-fold, TNF 3.2-fold, FGFR2 3.2-fold, PDGF-A
and PDGF-B 2.4-fold, and collagen XVIII 2.4-fold. Of those
involved in invasion and metastasis, matrix metalloproteinase
(MMP)2 was downregulated 8.3-fold, MTA1 4.3-fold, PLAU
4.3-fold, TIMP3 3-fold, S100A4 2.4-fold, SERPINE1 2.4-fold and
TWIST1 3.7-fold.
The only other genes in U2020 cells affected by ectopic
GLCE expression were cell cycle regulatory genes such as E2F-1
( 2.4-fold) and p21 ( 4.1-fold), the adhesion-related genes ITGA3
( 2.7-fold) and MCAM ( 2.4-fold), and signal transduction-
involved genes SNCG ( 6.2-fold), HER-2 ( 2.4-fold), Jun
( 3.2-fold) and AKT1 ( 3.2-fold).
From these results, we hypothesise that changes in the
expression levels of growth factors (VEGF-A, PDGF-A, PDGF-B,
TGFB1, TNFa, IGF1) and their receptors (FGFR2, TGFB1R,
TNFRSF10B, TNFRSF1A, TNFRSF25, FAS, HGFR/MET) may
underpin the anti-proliferative effects of GLCE in U2020 cells
in vitro (Figure 6).
Reduced growth factor expression, in combination with altered
expression of key adhesion molecules (ITGA3, MCAM, collagen
XVIII) may affect the adhesion, intercellular contacts and
signalling in epi-U2020 cells, thereby creating a more physiologi-
cally ‘normal’ microenvironment and restoring contact inhibition
of cell proliferation.
Taken together, these results show decreased GLCE expression
in lung cancer cell lines compared with the normal lung tissue.
Ectopic expression of GLCE in U2020 cells did not affect cell
viability, but did suppress cell proliferation in vitro and the growth
of experimental U2020 xenograft tumours in vivo. The in vitro and
in vivo results from the Cancer PathFinder Array suggest that the
anti-proliferative and anti-tumourigenic effects of GLCE in human
small-cell lung cancer cells are mediated via downregulation of key
growth factors and their receptors (particularly those involved
in angiogenesis).
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Figure 3 Ectopic expression of GLCE in U2020 small-cell lung cancer cells. (A) Representative multiplex RT–PCR gel showing GLCE expression in U2020
cells stably transfected with the pETE or epi-pETE plasmids (clones 4, 7 and 8). (B) GLCE expression levels normalised to that of GAPDH. The graph shows
the mean expression levels from triplicate experiments (±s.d.) (OriginPro 8.1). (C) Morphology of stably transfected pETE-U2020 cells and epi-U2020
cells (clone 7); magnification  100. (D) Immunocytochemical analysis of GLCE expression in pETE-U2020 and epimerase-U2020 cells using a custom
anti-epimerase polyclonal antibody. (E) Proliferation rates of the stable epi-U2020 and control pETE-U2020 clones (CyQUANT NF Cell proliferation assay).
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sDISCUSSION
The results of the present study show that GLCE suppressed the
proliferation of lung cancer cells in vitro, inhibited xenograft
tumour formation in vivo and GLCE inactivation was necessary for
the growth of experimental tumours in vivo. As shown previously
(Li et al, 1999), this is a strong evidence for a tumour-suppressor
function of GLCE in lung cancer.
A similar effect was shown previously for other HS-synthesising
enzymes, EXT1/EXT2, which are responsible for the polymerisa-
tion of the disaccharide-repeating regions within the growing HS
chains (Lind et al, 1998). EXT1 expression is silenced in human
cancer cells by epigenetic inactivation, and re-expression of EXT1
leads to the resumption of HS biosynthesis, reduced colony
formation density and tumour growth in nude mice (Ropero et al,
2004). Unexpectedly, targeted deletion of EXT1 does not lead to a
complete lack of HS synthesis. Indeed, two distinct cell lines
defective in EXT1 expression produce a small, but significant,
amount of HS chains (Okada et al, 2010), probably due to the
contribution of other EXT gene family proteins (Kim et al, 2001).
D-Glucuronyl C5-epimerase is a single-copy gene working
downstream of EXT1/EXT2 during HS biosynthesis. Epimerase
knock-out mice show a lethal phenotype with lung and kidney
defects (Li et al, 2003), suggesting the crucial importance of the
gene in lung and kidney development. The results of the present
study support an involvement of GLCE in lung carcinogenesis, and
show that the gene is a second candidate tumour-suppressor gene
related to the HS biosynthetic machinery along with EXT1.
According to the PathFinder Array results, three molecular
pathways were mainly affected by ectopic GLCE expression in
U2020 cells: apoptosis, angiogenesis and invasion/metastasis. With
regard to apoptosis, the main changes involved decreased
expression of TNF and TNF receptors (by 3–4-fold), which are
involved in the early stages of apoptosis signalling/initiation.
Taking into account the fact that expression of the main
components of the intracellular apoptotic machinery (BCL2,
BAD, BAX, CASP8, GZMA) remained unchanged and the viability
of epi-U2020 cells was not affected by ectopic expression of
epimerase, we suppose that the TNF/TNF receptors have a non-
apoptotic function in these cells. It may be that, in this case, the
TNF/TNF receptors functioned mainly in angiogenesis-related
events, and that the anti-mitotic effects of GLCE in U2020 cancer
cells were not directly related to apoptosis.
Regarding angiogenesis, the main changes involved decreased
expression of the pro-angiogenic growth factors, VEGF-A, PDGF-A,
PDGF-B, FGFR2, TGFB1 and TNF. Most of these factors are
upregulated in cancers. In particular, high expression of VEGF has
been observed in many cancers and is associated with a poor
prognosis (Azam et al, 2010). For example, VEGF expression
increases as bronchial carcinoma progresses (Merrick et al, 2005)
and is significantly increased in lung carcinomas (Brueckl et al,
2008). Over-expression of PDGF is linked to different types of
malignancy (Appelmann et al, 2010). FGFR2 expression is
significantly increased in cancer tissues (Marzioni et al, 2009)
and aberrant activation of FGFR2 signalling induces the prolifera-
tion and survival of tumour cells (Katoh and Katoh, 2009). TGF-b,
a tumour suppressor in normal or dysplastic cells, becomes a
tumour promoter in advanced cancers (Nagaraj and Datta, 2010).
Thus, the angiogenic growth factor ‘cocktail’ in cancers may be
biased towards VEGF and assorted other factors like PDGF, FGF,
EGF-like factors, angiopoietins (ANG1 and ANG2) or cytokines
such as IL8 (Schulz, 2005).
Ectopic expression of GLCE significantly decreased VEGF-A
expression (by 6.2-fold), as well as that of PDGF-A, PDGF-B and
FGFR-2, while the expression of other pro-angiogenic genes
(ANG1, ANG2 and IL8) remained unaffected. It is possible that
GLCE re-balances the growth factor ‘cocktail’ in favour of tumour
angiogenesis inhibition. If this is the case, then GLCE may be a
novel, natural regulator of angiogenesis and a possible target for
anticancer therapy.
The mechanism by which increased GLCE expression affects
growth factor expression and angiogenesis may act via changes in
the structure of cell surface and ECM proteoglycans. Many HSPGs
are involved in angiogenesis, including syndecans (Alexopoulou
et al, 2007), perlecan (Bix; Iozzo, 2005; Whitelock et al, 2008) and
glypican-1 (Aikawa et al, 2008). For example, perlecan modulates
VEGF–VEGFR2 signalling events during developmental angiogen-
esis (Zoeller et al, 2009); syndecans are necessary for FGFR
tyrosine kinase receptor function – syndecans that bind both bFGF
and FGFRs may act as stimulators of FGF signalling, whereas
syndecans that only bind bFGF may act as inhibitors (Zhang et al,
2009). Thus, the fine structure of syndecans (particularly their
HS chains) may provide the microenvironmental ‘context’ that
determines the pro-oncogenic or anti-oncogenic function of
FGFRs.
Several other studies show significant direct effects of HSPGs on
gene expression. For example, over-expression of syndecan-1
influences the expression profiles of other syndecans (Zong et al,
2010) and results in increased nuclear accumulation of FGF-2
(Zong et al, 2009). This suggests the existence of a general
mechanism for the regulation of gene expression by HSPGs.
Downregulation of GLCE expression/function in cancer cells
may affect the structure of all the HSs and alter the cell
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smicroenvironment, such that ‘normal’ angiogenesis switches to a
malignant process.
The most significant changes to the pathways involved in
invasion and metastasis were related to the downregulation of
MMP2, uPA (PLAU) and the metastasis-associated genes, MTA1
and S1004A. All are associated with a highly metastatic cell
phenotype. Matrix metalloproteinases are required for peritumour
tissue degradation and metastasis (Overall and Lo ´pez-Otı ´n, 2002),
and their expression is generally restricted to aggressive lung-
metastatic populations of cancer cells (Minn et al, 2005). uPA and
its inhibitor, PAI-I, have a key role in tumour invasion and
metastasis (Harbeck et al, 2004), and their expression levels are
increased in angiogenic non-small-cell lung tumours (Offersen
et al, 2007). MTA1 is a member of a newly discovered family of
cancer progression-related genes that are over-expressed in a wide
range of human cancers (Toh and Nicolson, 2009), and expression
of the metastasis-associated gene, S100A4, is strongly correlated
with an aggressive metastatic phenotype (Helfman et al, 2005).
Ectopic expression of GLCE in U2020 cells decreased the
expression of MMP2, uPA and the metastasis-associated genes,
MTA1 and S1004A. This suggests that GLCE may also have
potential anti-metastatic effects in vivo. Overall, the results of the
present study are consistent with those of previous work
investigating the anti-proliferative effects of GLCE over-expression
in breast cancer cells in vitro (Prudnikova et al, 2010). In both
cases, angiogenesis and invasion are thought to be the molecular
mechanisms affected by GLCE.
These in vitro results are supported by those from the in vivo
experiments comparing the relative expression levels of the same
genes in slow-growing xenografts (in which epimerase was
expressed) and grown xenografts (epimerase inactivated) (Mostovich
et al, 2010). Upregulation of IGF1, HTATIP2, BCL2, TNF, RB1,
TNFRSF6, IFNA1, IFNB1, ITGA1, ITGA3, SNCG, NME1, BCL2L1,
TGFB1 and FGFR2 in slow-growing xenografts coupled with the
d o w n r e g u l a t i o no fP D G F - A ,C F L A R ,I T G B 5 ,T N F R S F 1 0 B ,M M P 9 ,
–0.39
No change
No change
Apoptosis Angiogenesis
No change No change
Invasion and metastasis
MMP1
TIMP1
S100A4
PLAU
MMP9
TIMP3
MTA1
MMP2
SERPINE1
TWIST1
MTA2
NME1
NME4
SERPINB5
FAS
HGFR
ANGPT1
VEGFA
TGFB1
FGFR2
COL18A1
TNF
PDGFB
PDGFB
ANGPT2
IFNA1
IFNB1
IL8
THBS1
TEK
TGFBR1
IGF1
TNFRSF10B
HTATIP2
TNFRSF25
TNFRSFIA
TERT
APAF1
GZMA
CASP8
BCL2L1
BAX
CFLAR
p21
Cell cycle and repair
Group 1 vs control group Group 1 vs control group Group 1 vs control group
Group 1 vs control group Group 1 vs control group Group 1 vs control group
BRCA1
CDC25A
Cyclin E1
CDK2
CDK4
p16
p53
CHEK2
MDM2
RB1
E2F1
–0.89
–1.39
–1.89
–2.39
–2.89
–3.39
–3.89
–4.39
–4.89 –4.39 –3.89 –3.39 –2.89 –2.39 –1.89 –1.39 –0.89 –0.39
Log10 (control group 2^–deltaCt)
–4.35 –3.85 –3.35 –2.85 –2.35
BCL2
–1.85 –1.35
Log10 (control group 2^–deltaCt)
–3.48 –2.98 –2.48 –1.98 –1.48 –0.98 –0.48
Log10 (control group 2^–deltaCt)
–3.07 –2.57 –2.07 –1.57 –1.07 –0.57 –0.07
Log10 (control group 2^–deltaCt)
–3.1 –2.6 –2.1 –1.6 –1.1 –0.6 –0.1
Log10 (control group 2^–deltaCt)
–2.9 –2.65 –2.4 –2.15 –1.65 –1.4 –1.15 –0.9 –0.65
Log10 (control group 2^–deltaCt)
L
o
g
1
0
 
(
g
r
o
u
p
 
1
 
2
^
–
d
e
l
t
a
C
t
)
–1.35
–1.85
–2.35
–2.85
–3.35
–3.85
–4.35
–4.85
L
o
g
1
0
 
(
g
r
o
u
p
 
1
 
2
^
–
d
e
l
t
a
C
t
)
–0.07
–0.57
–1.07
–1.57
–2.07
–2.57
L
o
g
1
0
 
(
g
r
o
u
p
 
1
 
2
^
–
d
e
l
t
a
C
t
)
–0.1
–0.6
–1.1
–1.6
–2.1
–2.6
L
o
g
1
0
 
(
g
r
o
u
p
 
1
 
2
^
–
d
e
l
t
a
C
t
)
–0.48
–0.98
Signal transduction
No change
No change
ITGA1
ITGA2
ITGA4
ITGAV
ITGB1
ITGB3
ITGB5
MTSS1
PNN
SYK
ITGA3
MCAM
Adhesion
ETS2
AKT1
JUN
SNCG
ERBB2
RAF1
MAP2K1
PIK2R1
MYC
NFkB
NFKBIA
–1.48
–1.98
–2.48
–2.98
L
o
g
1
0
 
(
g
r
o
u
p
 
1
 
2
^
–
d
e
l
t
a
C
t
)
–0.65
–0.9
–1.15
–1.4
–1.65
–1.9
–2.15
–2.4
–2.65
L
o
g
1
0
 
(
g
r
o
u
p
 
1
 
2
^
–
d
e
l
t
a
C
t
)
Figure 5 Cancer PathFinder RT2 Profiler PCR Array analysis of epimerase-expressing U2020 cells. The relative expression levels for each gene in
epimerase-expressing U2020 cells (Group 1) are plotted against the same gene from the control pETE-U2020 cells (Control Group). The middle line shows
the similar expression in both groups with two-fold change boundaries. Genes upregulated greater than two-fold in epi-U2020 cells lie above the middle line
and the downregulated genes lie below the line.
1.00
0.87
0.41 0.42
0.32 0.31
0.27 0.31
0.33
0.71
0.26
0.81
0.16
0.99
0.50
e
p
i
-
U
2
0
2
0
 
v
s
 
p
E
T
E
-
U
2
0
2
0
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
0.00
IGF1
PDGFA
PDGFB
TGFB1
TGFBR1
FGFR2
VEGFA
HGFR
TNF
TNFRSF10B
TNFRSF1A
TNFRSF25
TNFRSF6
Figure 6 The relative expression of growth factors and growth factor
receptors in epimerase-expressing U2020 cells versus control pETE-U2020
cells. 1¼Equal expression levels in epimerase-expressing and control cells;
0.50¼two-fold decrease in expression.
D-Glucuronyl C5-epimerase suppresses lung cancer
EV Grigorieva et al
80
British Journal of Cancer (2011) 105(1), 74–82 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sANGPT1, SERPINE1, THBS1, ITGB3, p21, MET and ETS supports
the hypothesis that angiogenesis- and invasion-related genes may be
the downstream targets of epimerase in U2020 cells. The fact that the
expression of other molecules (for e.g., pro-apoptotic or cell cycle-
regulating genes) was also affected in the in vivo experiments may
reflect the complex nature of tumour–host interactions during
tumour development, where the surrounding cells and ECM
contribute to the overall expression profile.
Taken together, the results of the present study strongly suggest
that GLCE is a novel regulator of cancer cell proliferation and
tumour growth, and may be a promising target for lung cancer
diagnosis and treatment.
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